Introduction {#s1}
============

Macrophages are an innate immune cell type found in all tissues of the body with multiple functions. Tissue resident pools of macrophages arise from embryonic tissues during development, and are critical for normal tissue morphogenesis ([@B1]). During homeostasis, tissue macrophages are maintained primarily through local proliferation. In chronic inflammatory processes such as cancer, hematopoietic derived monocytes circulate through the blood and infiltrate tissues where they terminally differentiate into macrophages to, in part, replenish resident pools as well as increase macrophage levels for the remediation of infection or structural damage ([@B2]). Macrophages display a spectrum of opposing yet complementary behaviors depending on the signals they receive from the local microenvironment ([@B3]). Traditionally, macrophage activation has been characterized using a dichotomous spectrum, with the two extremes being "classically activated" or pro-inflammatory macrophages and "alternatively activated" or pro-remodeling, immunosuppressive macrophages. Classically activated macrophages (termed M1) phagocytize microbes and secrete cytokines such as interleukin 6 (IL-6), TNF-α, and IL-1β, as well as nitric oxide (NO) and reactive oxygen species during host defense in response to stimulation by interferon-γ (IFN-γ) and toll-like receptor ligands, including bacterial lipopolysaccharide (LPS). Alternatively activated macrophages (termed M2) are stimulated primarily by the T~h~2 cytokines IL-4 and IL-13 and facilitate extracellular matrix (ECM) remodeling, blood vessel formation, and dampen immune activation by secreting cytokines such as IL-10 and TGF-β ([@B4], [@B5]). In recent years it has become apparent that the dichotomous M1/M2 model is an oversimplification of the behavioral spectrum of macrophages, with many unique transcriptional profiles being identified in response to differing activation signals ([@B6]). As such, it is now recommended to denote macrophage states by the activating stimulus (e.g., M~LPS+IFNγ~ or M~IL4+IL13~) ([@B7]). Macrophage activation states have been characterized extensively in murine and *in vitro* models. However, the exact genetic profiles and functional outputs, such as NO production ([@B8], [@B9]), for example, differ from human macrophage states and the relevance of murine studies to human macrophage biology is still under debate. Nonetheless, both major macrophage phenotypes are required for maintaining tissue homeostasis, but each, respectively, can play a role in the pathogenesis of diseases including atherosclerosis and cancer ([@B10]).

Macrophages and the Extracellular Matrix in Cancer {#s2}
==================================================

In cancer, macrophages infiltrate the tumor microenvironment (TME) in response to tumor-secreted chemotactic signals and exhibit a tumor-supportive phenotype similar to the M2 phenotype. High macrophage infiltration has been associated with a poor prognosis and increased rates of metastasis in several cancer types, as tumor-associated macrophages (TAMs) can facilitate blood vessel formation to support expanding tumor growth and aid tumor cell intravasation into vasculature ([@B5], [@B11]--[@B13]). Much work has been done to characterize soluble factors present in the TME that recruit and influence macrophage behavior ([@B14]), however less is known about how the mechanical properties of tumor ECM impact macrophage recruitment, activation, and cytokine secretion.

Many cancers, including breast cancer, exhibit aberrant deposition, and organization of extracellular matrix proteins surrounding a tumor ([@B15]--[@B18]). The ECM is comprised of several fibrous and non-fibrous proteins including collagens, laminins, fibronectin, and others that are deposited and organized into a stromal meshwork that supports cellular growth and migration. Indeed, dense breast tissue is a strong and prevalent risk factor for the development of invasive breast cancer and is associated with excess collagen deposition and tissue stiffness ([@B19]--[@B23]). Recent studies demonstrate that even in healthy patients, mammographically dense tissue increases pro-tumor inflammation and overall immune infiltration, including CD68+ macrophages and CD20+ B lymphocytes surrounding the vasculature, which may be part of the underly mechanism driving this risk of developing breast cancer ([@B24]). In breast cancer patients, the reorganization of collagen that accompanies tumor progression results in aligned fiber bundles at the tumor-stromal boundary and, importantly, this signature of collagen predicts disease outcome ([@B18], [@B25]). Along these lines, in invasive ductal carcinoma biopsy tissue, the association of anti-inflammatory CD163+ macrophages and aligned collagen fibers is predictive of poor patient outcome ([@B26]). Macrophages have been shown to play a role in matrix organization through the secretion of matrix metalloproteinases to degrade and reorganize the matrix as well as aid in tumor cell migration ([@B27]). Moreover, tumor associated macrophages have been shown to facilitate the deposition of aligned collagen fibers during tumor development ([@B28], [@B29]).

As monocytes circulate toward tumor signals they encounter soluble plasma matrix proteins, such as fibronectin and fibrinogen, known to be upregulated in breast cancer patients and associated with poor prognosis ([@B30], [@B31]). The binding of these ECM proteins to adhesion receptors on the surface of macrophages promote inflammatory and tumor-promoting macrophage activation ([@B32]--[@B34]) ([Figure 1A](#F1){ref-type="fig"}). Within tumor stroma, collagen along with fibronectin and laminin have been shown to promote tumor cell proliferation, angiogenesis, and dissemination ([@B35], [@B36]). Alterations in ECM organization and composition in the tumor microenvironment result in increased matrix stiffness, primarily localized to the invasive front of breast tumors. These stiff regions are enriched in aligned collagen fibers, tumor-activated macrophages (CD163+) and the activated form of β1-integrin ([@B23]). Similarly, accelerated tumor progression was accompanied by an overall increase in macrophages and tumor cytokines, including CCL2, in a collagen-dense mammary tumor model compared to controls ([@B37], [@B38]). Moreover, CCL2 recruits Tie2 expressing macrophages to facilitate early tumor cell dissemination ([@B39]). This process involves a mechanism by which macrophages lead tumor cells through reciprocal chemokine signaling along collagen coated substrates and toward vascular endothelium *in vitro*. Importantly, the same mechanism of macrophage-tumor cell migration has been observed *in vivo*, where macrophage-tumor cell trafficking can be visualized along collagen fibers ([@B40], [@B41]). Together, these studies suggest that matrix stiffness increases CCL2 levels, which in turn recruits specific macrophage populations that interact with collagen fibers and facilitate tumor cell dissemination. Thus, it is becoming clear that macrophages are sensitive to changes in the ECM and their mechanical environment, however the causal link between ECM biophysical properties and the functional activation of TAMs *in vivo*, in animal models as well as in humans, is still unclear.

![Schematic of biophysical cues from the ECM to activate integrin signaling on macrophages in the TME. **(A)** Inset depicts integrins on the surface of monocytes within the lumen of a blood vessel. Integrin engagement activates monocytes in circulation and facilities transendothelial migration into the TME. **(B)** Macrophage localized in a region of increasing matrix stiffness. Matrix stiffness results in integrin clustering and focal adhesion signaling. Downstream of integrins there is an increase in the PI3K/Akt pathway to activate NF-kB transcriptional activity as well as actin/myosin generated cellular contractility leading to directional migration. Further investigation is required to determine whether integrin signaling regulates other markers of macrophage activation.](fonc-10-00787-g0001){#F1}

Mechanical Regulation of Macrophage Polarization {#s3}
================================================

Growing appreciation for biophysical cues from the extracellular matrix to drive cellular phenotypes has led to a large body of work demonstrating that ECM topography, composition, stiffness, and other mechanical loading modalities are capable of modulating macrophage function *in vitro*. The field of macrophage mechanobiology has largely stemmed from the biomaterials and implant fields. These fields have found that changing surface topography by increasing surface roughness generally results in increased macrophage adhesion and alterations in cytokine secretion, but the mechanisms by which roughness impacts macrophage responses depends on the method and the macrophage cell types used for investigation ([@B42]--[@B44]). Other studies have demonstrated that substrate stiffness, which is associated with enhanced breast tumor progression, is another mechanical aspect of the ECM that can influence macrophage behavior ([Figure 1](#F1){ref-type="fig"}). Increasing the stiffness of biologic and engineered substrates resulted in increased migration of unstimulated macrophages, and inflammatory macrophage cytokine production ([@B45], [@B46]). However, it should be noted that these increases are accompanied by altered integrin expression levels as well as increased myeloid differentiation response protein 88 (MyD88)-dependent NF-κB activation through TLR activation, and that NF-κB has been shown to regulate anti-inflammatory gene expression as well ([@B47]). Additionally, these effects are independent of collagen I and laminin stimulation and may be the result of cytoskeletal signaling rather than integrin engagement.

Changes in cell shape and the cytoskeleton are also frequently observed with increasing substrate stiffness and can in themselves alter macrophage activation. In general, M1 macrophages are uniformly spread, with a circular morphology ([@B45], [@B48]). Inflammatory activation is inhibited when bone marrow derived macrophages (BMDMs) are confined to small pores rather than allowed to spread freely, through a mechanism involving actin dynamics and signaling through the MRTF-A-SRF complex ([@B49]). However, elongation of macrophages produces a different phenotype. Macrophages elongated on 2-D engineered nano-substrates consistently correlates with anti-inflammatory gene expression profiles across a variety of surfaces and cell lines at late time points (\>24 h) and when cells are allowed to spread along wider grooves (\>450 nm widths). Furthermore, macrophage elongation increases expression of adhesion receptors, actin-based contraction and enhances activation by IL-4/IL-13, while preventing elongation attenuates these cytokines\' ability to activate the macrophages ([@B45], [@B48], [@B50], [@B51]).

In many of these studies, it appears that mechanical stimuli may work in conjunction with soluble factors to induce macrophage activation. Nevertheless, mechanical stimulation likely plays an equally important role in priming macrophages to become activated toward a specific phenotype, however the exact cellular mechanisms and intracellular signaling pathways that mediate this still require further investigation. Therapeutically, there is potential to modulate macrophage behavior via mechanical regulation, however the application of this knowledge in the context of cancer remains limited, as more work is required to characterize the mechanical dynamics present within the TME. Presently, there are few therapies that directly target ECM stiffness or organization. Therefore, understanding how the ECM can modulate the activity of soluble signals on macrophages in the TME, through adhesion receptors and the cytoskeleton for example, may provide insights into improving existing therapies that target cytokine and growth factor signaling.

Integrin Adhesion Signaling in Macrophage Activation {#s4}
====================================================

Overview
--------

As previously eluded to, mechanical cues from the ECM can be detected by macrophages through the integrin family of heterodimeric adhesion receptors, and many integrins are differentially expressed by classically and alternatively activated macrophages ([@B45]). Integrins consist of an alpha and beta subunit. Each alpha and beta combination has a unique binding affinity for certain matrix proteins, however each integrin often has multiple ECM ligands. Upon ligand binding, integrins transduce signals inside of the cell via adapter proteins such as focal adhesion kinase (FAK), talin, vinculin, and others that couple integrins to the cytoskeleton (outside-in signaling) ([@B52]). Changes in cytoskeletal organization have a direct impact on several transcription factors, including MRTF-A, YAP and NF-κB, which facilitate changes in gene transcription that are potentially related to macrophage function. Several integrins are expressed by macrophages ([Table 1](#T1){ref-type="table"}), the most common being the β2 family of integrins which are unique to leukocytes. Although integrin signaling has traditionally been overlooked when investigating macrophage activation, several studies have demonstrated that integrin-ECM adhesion initiates signaling pathways that can in fact influence macrophage activation. Based on these studies the concept emerges that biophysical cues from the ECM regulate macrophage activation, in part, through integrin engagement and signaling ([Figure 1](#F1){ref-type="fig"}).

###### 

Integrins expressed on the surface of murine macrophages.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                **Integrin**   **ECM Ligands**                                               **Other ligands**                           **Main functions**                                 **References**
  ------------- -------------- ------------------------------------------------------------- ------------------------------------------- -------------------------------------------------- --------------------------
  *β2 Family*   **αLβ2**\      None.                                                         ICAM-1 ICAM-3 ICAM-2 ICAM-5 JAM-1           Endothelial transmigrationIntercellular adhesion   ([@B53]--[@B56])
                CD11a/CD18\                                                                                                                                                                 
                LFA-1                                                                                                                                                                       

                **αMβ2**\      Fibronectin Vitronectin Fibrinogen Laminins Collagens Cyr61   ICAM-1\                                     Migration\                                         ([@B57]--[@B60])
                CD11b/CD18\                                                                  ICAM-2\                                     Complement Receptor Type 3\                        
                Mac-1 CR3                                                                    ICAM-3\                                     Phagocytosis\                                      
                                                                                             iC3b\                                       Trans-endothelial extravasation                    
                                                                                             Thrombospondin\                                                                                
                                                                                             CD23\                                                                                          
                                                                                             NIF\                                                                                           
                                                                                             LPS\                                                                                           
                                                                                             \[for complete list please see ([@B57])\]                                                      

                **αXβ2**\      Fibrinogen                                                    ICAM-1\                                     Complement Receptor Type 4\                        ([@B60]--[@B67])
                CD11c/CD18\                                                                  ICAM-4\                                     Intercellular adhesion\                            
                P150,95\                                                                     CD23\                                       Fibrinogen adhesion                                
                CR4                                                                          LPS\                                                                                           
                                                                                             Thy-1\                                                                                         
                                                                                             iC3b\                                                                                          
                                                                                             Plasminogen                                                                                    

                **αDβ2**\      Fibronectin Vitronectin Fibrinogen\                           ICAM-3\                                     Migration\                                         ([@B68]--[@B70])
                CD11d/CD18     Cyr61                                                         Plasminogen\                                Cell adhesion                                      
                                                                                             P2-C                                                                                           

  *β1 Family*   **α2β1**\      Collagens Laminins                                            Echovirus 1                                 Migration\                                         ([@B71]--[@B73])
                *VLA-2*\                                                                                                                 Cell adhesion                                      
                *CD49b/CD29*                                                                                                                                                                

                **α4β1**\      Fibronectin\                                                  VCAM-1                                      Migration\                                         ([@B71], [@B74], [@B75])
                *VLA-4*        EMILIN1                                                                                                   Intercellular adhesion                             

                **α5β1**\      Fibronectin                                                   RGD Sequences                               Fibronectin receptor\                              ([@B71], [@B76], [@B77])
                *VLA-5*                                                                                                                  Migration                                          

                **α6Aβ1**\     Laminin (not in macrophages, however)\                        --                                          Adhesion                                           ([@B71], [@B78])
                *VLA-6*        Fibronectin                                                                                                                                                  

  *β3 Family*   **αVβ3**\      Vitronectin\                                                  VWF\                                        Vitronectin receptor\                              ([@B58], [@B77], [@B79])
                *CD51/CD63*    Fibrinogen                                                    Thrombospondin\                             Adhesion                                           
                                                                                             RGD Sequences                                                                                  

  *β5 Family*   **αVβ5**       Vitronectin\                                                  MFG-E8                                      Phagocytosis\                                      ([@B80]--[@B82])
                               (Fibrinogen and Fibronectin, minimally)                                                                   Debris clearance                                   
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*Integrin names are listed using α and β chain nomenclature with commonly used alternative names listed underneath*.

Effects of Integrin Activation on Macrophages
---------------------------------------------

The αMβ2 integrin (also commonly referred to as CD11b/CD18 and Mac-1, among others) is the most promiscuous integrin of the β2 integrin family. It is also the most studied of the integrins expressed by macrophages, however its impact on macrophage activation remains disputed. In *Itgam*^−/−^ (αM deficient) mice, tumor growth and immunosuppressive cytokine mRNA levels are enhanced relative to wild type mice, whereas constitutive activation of the αM integrin by a point mutation knock in (C57BL/6 ITGA-M ^I332G^) inhibits tumor growth, despite increased IL-6 mRNA levels ([@B83]). In contrast, Han et al. argue that inflammatory cytokines are upregulated in *Itgam*^−/−^ mice (relative to *Itgam*^+/−^ control mice) when challenged with TLR ligands ([@B84]). However, this increase is measured from serum and global knockout of αM likely impacts other immune cell types, such as dendritic and natural killer cells, which could contribute to this finding. αMβ2 expression is upregulated in stiff, photo-induced cross-linked fibrin gels ([@B45]) and by the inflammatory stimuli LPS/ IFN-γ. Its expression is also inhibited by TGF-β, a protein that is abundant in the TME and may contribute to tumor-directed immune suppression ([@B83]). On the other hand, work by the Xuetao Cao group has shown that TLR-mediated αMβ2 activation, that leads to downstream Src and Syk activation, is capable of promoting alternative activation in murine macrophages via a IL-4-STAT6-Jak1 and MyD88-TRIF-Cbl-b mediated mechanism, respectively ([@B84], [@B85]). Additionally, lysyl oxidase (LOX)-mediated collagen crosslinking within the primary and pre-metastatic TME aids in the retention of myeloid cells expressing the αMβ2 integrin. The αMβ2+ macrophages secrete MMPs to continue to reorganize the ECM, further contributing to increased macrophage levels in primary and metastatic breast tumors ([@B23], [@B86], [@B87]).

In addition to αMβ2, collagen specific adhesion receptors have also been shown to mediate macrophage activation. The importance of macrophage adhesion to collagen is underscored by the fact that the ECM in human primary breast cancers contains higher levels of collagen (I, III, IV, XIII) compared to normal breast tissue ([@B88], [@B89]). The α2β1 integrin mediates macrophage migration and adhesion to type 1 collagen. A study by Cha et al. showed that α2β1, vinculin, PTK2, and the alternatively activated macrophage-associated marker CD206 are significantly upregulated by macrophages differentiated from THP-1 monocytes on hydrogels that allow for cell adhesion. Furthermore, this adhesion-mediated signaling augments the effects of IL-4 treatment. When α2β1 ligand binding is blocked with a neutralizing antibody, CD206 expression is significantly downregulated and cannot not be induced by the addition of IL-4, demonstrating that α2β1 engagement is important for alternative activation ([@B90]). Independent of soluble factors, it has also been shown that macrophages are able to sense mechanical deformations of the ECM from fibroblast contractions, and that these deformations alone are able to induce α2β1 mediated macrophage migration toward the fibroblasts ([@B91]). High numbers of cancer-associated fibroblasts are often observed in tumors, suggesting that cellular contractions from cancer-associated fibroblasts may dramatically deform the ECM to potentially aid the recruitment of α2β1-expressing TAMs locally. Moreover, scavenger receptor A (SR-A) and CD36 mediate macrophage adhesion to modified or denatured forms of type I and IV collagen, which are often found in inflammatory conditions ([@B92]--[@B94]). CD36 is upregulated in alternatively activated macrophages ([@B95]), and SR-A is upregulated by macrophages when co-cultured with cancer cells ([@B96]). Interestingly, SR-A expressing TAMs colocalize in the stroma of tumors with FAP+ cancer associated fibroblasts that cleave collagen fibers to enhance TAM retention via SR-A mediated adhesion ([@B94]). SR-A-mediated macrophage adhesion plays an important role in cancer, as demonstrated by the prevention of ovarian cancer progression in mice treated with SR-A inhibitors ([@B96], [@B97]).

Several other ECM protein ligands bind integrins expressed by macrophages. The β3 integrin is required for macrophage trans-endothelial migration on the ECM protein vitronectin. In human peripheral monocyte derived macrophages, ligand binding to αVβ3 integrins activates a PI3-K/Akt signaling cascade resulting in NF-κB mediated gene expression and pro-inflammatory cytokine secretion. Interestingly, this pathway is synergistically enhanced by LPS/TNF-α stimulation ([@B98]). In contrast, in murine BMDMs β3 expression was seen to be significantly higher in M~IL4+IL13~ macrophages compared to M~LPS+IFNγ~, and its knockdown resulted in increased TNF-α secretion relative to the non-treated control ([@B45]). Additionally, the β4 laminin binding integrin is upregulated on the surface of TAMs in triple negative breast cancer. In combination with TGF-β signaling, ligand binding to β4 leads to increased integrin clustering and adhesion to lymphovasculature, which aids tumor cell dissemination ([@B99]).

Integrins are critical for cellular migration, and while macrophages are capable of utilizing both amoeboid and mesenchymal modes of migration, certain integrins may enhance macrophage migration in parallel with chemotactic signals. Macrophages can sense increases in fibronectin within the TME via the α5β1 integrin ([@B58]). β1 binding to fibronectin can couple with CSF1R, a master regulator of macrophage function and survival, on the plasma membrane leading to CSF1R-mediated phosphorylation via SFK/FAK ([@B100]). CSF1R has been strongly implicated in the recruitment and regulation of tumor promoting activities of TAMs ([@B101]), and is necessary for macrophage migration on fibronectin ([@B100]). Some have suggested that inflammatory signaling is required to prime integrins into the active state, allowing for increased ligand binding and signal transduction responsible for gene transcription, and interactions between adhesion and cytokine receptors lends strength to this argument ([@B58]).

Studying Macrophages *in vivo* {#s5}
==============================

Challenges
----------

Many challenges still exist when investigating macrophage biology, both *in vitro* and *in vivo*. The inconsistent findings from many of the studies discussed here can potentially be attributed to differences in cell lines, surface chemistries, time points analyzed, and other variables, but nonetheless emphasize the important fact that commonly used macrophage cell lines and primary cells exhibit differing responses to identical stimuli, often making *in vitro* findings difficult to compare. This is true for both murine ([@B4], [@B102], [@B103]) and human ([@B104], [@B105]) cell sources. Additionally, there are many differences between human and murine macrophage biology, from surface marker expression to metabolic states, that can result in stark differences in functional output ([@B106]--[@B108]). Species specificity of macrophage cell types and the presence or absence of serum factors from humans vs. other species used in *in vitro* studies may also limit the applicability to human biology and therapeutic strategies. Thus, further studies are required to delineate murine and human macrophage responses, not only in mechanical studies.

Additional challenges exist when identifying the activation state of a macrophage, especially *in vivo*. Traditionally, phenotypes are identified using immunohistochemistry and transcriptional profiling, however these techniques require multiple markers to confirm an activation state and are most useful in *in vitro* or *ex vivo* studies at end stage time points. There is a great need for techniques to identify phenotypes through protein expression *in vivo*. While the use of genetically encoded fluorescent proteins to readout macrophage activation is possible, the use of multiple markers to confirm macrophage identity and the unintended effects of introducing exogenous proteins limits feasibility. Another area of concern, particularly in studies investigating mechanical regulation of macrophages is the fact that macrophages respond differently to substrates in 2-D compared to 3-D. Currently, most studies are performed using 2-D methods to investigate migration and activation. There is a great need for more studies investigating macrophages in 3-D, especially in the context of cancer, as it is more representative of the environment macrophages naturally reside in. It is imperative to improve methods of investigating macrophages in their native environments so as to minimize variances that arise from culture and experimental conditions, and to best elucidate the impact of the ECM on macrophages.

Current Approaches
------------------

In order to observe macrophages in the tumor microenvironment, the field has recently turned to optical approaches such as positron emission tomography (PET), for example \[reviewed extensively in ([@B109])\]. Rostam et al. have proposed image-based machine learning to identify phenotypes based on cellular morphology which, as described earlier, may provide some indication of phenotype ([@B110]). The availability of 3-D culture platforms to investigate macrophage--tumor cell interactions provide a tool kit to identify macrophage phenotype in more *in vivo*-like microenvironments ([@B111]--[@B113]). Using these platforms, one can take advantage of pharmacologic and optogenetic approaches to manipulate adhesion receptor activation and downstream signaling pathways involved in macrophage responses to biophysical cues from the ECM ([@B114]--[@B116]).

In addition to PET and single-photon emission computed tomography (SPECT) ([@B109]), another technique, intravital imaging, utilizes small implanted imaging windows paired with confocal or multiphoton microscopy to visualize the spatial organization of tumor and stromal cell populations ([@B117], [@B118]). Cell-type-specific expression of proteins that are genetically fused with fluorescent tags, such as GFP or mCherry, as well as the endogenously fluorescent metabolic cofactors FAD^+^ and NADH ([@B119]) can be used to identify macrophage, tumor, and other cell types in the mouse ([Figure 2](#F2){ref-type="fig"}). This technique has facilitated direct observation of macrophages interacting with and assisting tumor cells to intravasate into nearby vasculature, as well as tumor cell extravasation at distant metastatic sites ([@B121], [@B122]). While this approach provides detailed spatial and temporal resolution of cells in the TME, there is still a lack of validated signatures to fully identify and characterize macrophage phenotypes *in vivo*. One emerging signature of macrophage activation is the use of fluorescence lifetime. Fluorescence Lifetime Imaging Microscopy (FLIM) reports the time a fluorophore remains in the excited state before transitioning back to ground state, and differences in fluorescent lifetimes of NADH and FAD^+^ can indicate whether the cofactors are free or protein bound. Changes in the relative concentrations of bound vs. free NADH and FAD^+^ can provide information on metabolic states at the single cell level ([@B123], [@B124]). Within the TME, Szulczewski et al. demonstrated that stromal macrophages have a distinct NADH FLIM signature, allowing them to be distinguished from tumor cells ([@B119]). Along these lines, Alfonso-Garcia et al. show stark differences in the NADH fluorescence lifetime signatures in M~LPS+IFNγ~ and M~IL4+IL13~ induced BMDMs *in vitro* ([@B125]), thus warranting further investigation into the use of FLIM to identify macrophage activation *in vitro* and *in vivo*. In addition to endogenous and genetically expressed fluorescence, ported mammary imaging windows that feature a needle inserted through the window base have been used to inject fluorescently conjugated antibodies. This methodology provides an opportunity for real-time visualization of the localization and relative abundance of cell type specific proteins, such as macrophage activation markers and integrins.

![Intravital imaging of mammary carcinoma in a MMTV-PyMT mouse. 2-photon scanning laser microscopy allows for the *in vivo* observation of tumor cells (high in NADH intensity, 780 nm excitation), collagen fibers through second harmonic generation (890 nm excitation), and **(A)** Macrophages expressing the fluorescent mCherry protein under the CSF1-R promotor (C57BL/6-Tg(Csf1r-HBEGF/mCherry)1Mnz/J X B6.129P2-Lyz2^tm1(cre)Ifo^/J) ([@B120]) (1050nm excitation). **(B)** FAD^HI^ cells which depict primarily macrophage stromal cells ([@B119]). **(C)** NADH fluorescence lifetime overlay on mask of mCherry+ cells (color map of NADH τm lifetime). **(D)** Insets depict mcherry^+^ macrophages, which are FAD bright, spatially localized in the collagen rich stroma or within the tumor mass. Arrow indicates a macrophage spread in a collagen abundant region of the tumor stroma. Dashed outline depicts a macrophage elongated in an aligned region of collagen fibers at the boundary of a tumor nest.](fonc-10-00787-g0002){#F2}

Conclusion {#s6}
==========

Taming tumor-associated macrophages has been a long-time goal for cancer therapy, and much work remains to fully understand the crosstalk between macrophages and the tumor microenvironment. While a causal mechanistic link between biomechanical properties of the ECM and macrophage activation has yet to be fully established *in vivo*, here we highlight studies that investigate the relationship and crosstalk between biophysical properties of the ECM and macrophage activation. Further investigation into downstream signaling pathways activated by integrin ligand binding and mechanical stimuli is necessary to identify potential therapeutic interventions to shift TAMs away from a tumor promoting phenotype. One expanding area is the use of metabolic reprogramming to shift macrophage phenotypes. Classically and alternatively activated macrophages favor differing metabolic mechanisms, and differences in the fluorescence lifetime signatures of metabolic cofactors lends support to the use of metabolism as a phenotypic marker. Moreover, integrin activation through the α2β1 integrin can induce activation the PI3K-Akt pathway ([@B126]), and macrophage metabolism is strongly regulated by PI3k-Akt-mTOR signaling which can prime macrophages toward either activation state depending on confounding biochemical stimuli in the TME such as hypoxia or IL-4 ([@B127]). Metabolism provides an attractive target for manipulation, as it is highly sensitive and fast responding to changes inside and outside the cell, critical characteristics for macrophages to alter their activation in an inducible and reversible manner.
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